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Over the past two decades, molecular targeted diagnostic and therapeutic agents have
dramatically improved cancer diagnosis and treatment.[1–8] Targeting allows the preferential
delivery of therapeutic, diagnostic, or imaging agents to the intended site. Advances in
nanotechnology have enabled the development of a variety of targeted nanoparticle
platforms for diagnostic and therapeutic applications.[9–11] Preclinical data have shown that
targeted nanoparticle systems accumulate preferentially in the target tissue, demonstrating
the vast potential of targeted nanoparticles.[12–14] In addition, the development of
multifunctional nanoparticle platforms, with both diagnostic and therapeutic capabilities,
may allow in vivo monitoring of both biodistribution of the nanocarriers and tumor response
to therapy.[11, 15–17] Therefore, research efforts have been focused on the further
development of multifunctional molecular agents for the diagnosis and treatment of cancer.
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One of the most promising diagnostic agents is superparamagnetic iron oxide nanoparticles
(SPION).[18] SPION have several important advantages over traditional gadolinium-based
magnetic resonance (MR) contrast agents: lower toxicity, stronger enhancement of proton
relaxation, and lower detection limit.[19, 20] Ferumoxtran-10 (Combidex), a dextran-coated
SPION with a mean diameter of ~30 nm, is currently in phase III clinical trials for prostate
cancer (PCa) imaging.[21] Combidex has a 90.5 % sensitivity and 97.8 % specificity for
detecting PCa lymph node disease by passively accumulating in metastatic nodes.[22] The
major shortcoming of Combidex is its inability to detect PCa disease outside of the lymph
nodes.
Herein, we report the development of a novel, multifunctional, thermally cross-linked
SPION (TCL-SPION) that can both detect PCa cells, and deliver targeted chemotherapeutic
agents directly to the PCa cells. We previously reported the use of the A10 RNA aptamer
(Apt), which binds the extracellular domain of the prostate-specific membrane antigen
(PSMA), to engineer targeted nanoparticles for PCa therapy and imaging.[12, 13, 23] PSMA is
a well-established marker for PCa cells, with relatively low levels of expression in normal
prostate, kidney, brain, and small intestine tissue.[24] The percentage of PCa cells that
express PSMA approaches 100 % with highest expression in androgen-independent PCa
cells.[25, 26] Additionally, we have shown that the A10 aptamer can be used to deliver
doxorubicin (Dox), a chemotherapeutic agent, by intercalation of Dox into the CG sequence
in the aptamer.[23, 27, 28] By combining the above concepts, we have formulated SPION–Apt
bioconjugates for combined PCa imaging and therapy. The components of the nanoparticle
include: a) N-terminated A10 aptamer, a 57-bp nuclease-stabilized 2′-fluoropyrimidine RNA
molecule modified with C18-amine at the 3′ end, for targeting PSMA-expressing PCa cells,
and acting as a carrier for Dox; b) TCL-SPION coated with a carboxylic acid-PEG-derived,
anti-biofouling polymer,[29] which acts as both a MR contrast agent and as a carrier for Dox;
and c) Dox, a chemotherapeutic agent that is intercalated in the aptamer and complexed with
the TCL-SPION through charge interactions. The hydroxy and carbonyl groups on the
surface of the TCL-SPION make them apt for the formulation of targeted nanoparticle
platforms. The PEGylated surface prevents protein and cell adsorption, while the carboxyl
groups allow conjugation of targeting moieties, like the A10 aptamer. TCL-SPIONs are also
well suited for therapeutic delivery because of their low toxicity profiles.[30–32]
Conjugation of the TCL-SPION with an A10 aptamer, using standard coupling chemistry,
gave the TCL-SPION–Apt bioconjugate formulation (Figure 1 a); conjugation led to an
increase in both size (60.8±1.9 to 66.4±1.5 nm), and ζ-potential (−36.0±1.8 to −42.7±3.8
mV) of the nanoparticles. The conjugation of the A10 aptamer to TCL-SPION was
confirmed using agarose gel electrophoresis (Figure 1 b); the free A10 aptamers matched the
60-bp band in the 100-bp ladder, and the TCL-SPION–Apt bioconjugate lane showed a band
at a much higher molecular weight, confirming the conjugation of Apt to TCL-SPION.
Differential uptake of the TCL-SPION–Apt bioconjugate by PSMA-expressing PCa cells
(LNCaP), compared with non-PSMA-expressing PCa cells (PC3), was then confirmed in
whole-cell assays by comparison with the uptake of TCL-SPION . Monitoring the uptake at
regular time intervals (1, 3, 6, 12, 18 and 24 h) and using the Prussian blue reaction to
visualize uptake, intracellular TCL-SPION–Apt bioconjugate uptake in LNCaP cells was
detected as early as 3 h after dosing and progressively increases in a time-dependent manner.
In contrast, TCL-SPION–Apt bioconjugates incubated with PC3 cells, and TCL-SPION
incubated with LNCaP and PC3 cells, did not show intracellular uptake of the nanoparticles
(Figure 2). These results confirm that TCL-SPION–Apt bioconjugates can differentially
target PSMA-expressing PCa cells.
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The potential of the TCL-SPION–Apt bioconjugate as a targeted MR contrast agent was
investigated by NMR studies. The longitudinal relaxation time (T1), and the transverse
relaxation time (T2) of the TCL-SPION–Apt bioconjugate and non-targeted TCL-SPION
was measured using a single-sided NMR probe, after incubation with LNCaP and PC3 cells
(6 h), and resuspension in Matrigel to simulate prostate tumors. Only a small change in T1
and T2 was observed for the non-targeted TCL-SPION in LNCaP cells (T1: 1939±116 to
1521±201 ms; T2: 104.2±1.4 to 89.8±1.1 ms), however, the TCL-SPION–Apt bioconjugate
led to a dramatic decrease in T1 and T2 (T1: 1939±116 to 263±23 ms; T2: 104.2±1.4 to
26.6±0.4 ms). As expected, TCL-SPION–Apt bioconjugates did not lead to significant
reduction of T1 and T2 relaxation times in PC3 cells (Figure 3). These data suggest that
TCL-SPION–Apt bioconjugates can detect PSMA-expressing PCa cells with high
sensitivity.
After demonstrating the TCL-SPION–Apt bioconjugate’s potential as a targeted MRI
contrast agent, its potential as a therapeutic carrier was investigated. Firstly, the amount of
Dox that can bind to the TCL-SPION–Apt bioconjugate through intercalation into the
aptamer, and adsorption into the negatively charged polymer surface of the nanoparticle was
determined. We had previously shown that the conjugation of Dox results in the quenching
of its fluorescence.[27, 33] Using a spectrofluorophotometer, we titrated increasing
concentrations of TCL-SPION and TCL-SPION–Apt bioconjugate against a fixed amount of
Dox. As seen in Figure 4, the amount of TCL-SPION and TCL-SPION–Apt bioconjugates
needed to quench 12 μg of Dox were 0.52 and 0.44 mg, respectively, giving loading
efficiencies of 23.1 μg Dox mg−1 and 27.3 μg Dox mg−1 respectively. From the titration
data, approximately 15 % of Dox was intercalated in the aptamer and approximately 85 %
was bound to the polymer by electrostatic interactions.
The Dox-loaded TCL-SPION–Apt bioconjugates were evaluated for antiproliferation
activity against both the LNCaP and PC3 cell lines (Figure 5). While free Dox was
equipotent against both LNCaP and PC3 cell lines, the Dox-loaded TCL-SPION–Apt
bioconjugate was significantly more potent against the PMSA-expressing LNCaP cells
relative to the non-targeted PC3 cells (cell viability: LNCaP 47.3±1.4 % vs. PC3 69.3±1.7
%). The data also showed that the cytotoxicity of Dox-loaded TCL-SPION–Apt
bioconjugates was nearly as potent as free Dox. The observed cytotoxicity of Dox-loaded
TCL-SPION–Apt bioconjugates to PC3 cells (69.3±1.7 % compared with 95.7±1.9 % of
control) was likely due to uptake of Dox released after the dissociation of Dox from TCL-
SPION–Apt bioconjugates.
In summary, a novel multifunctional TCL-SPION–Apt bioconjugate was synthesized, and
shown to detect and treat PCa cells in vitro. However, the potential of TCL-SPION–Apt
bioconjugates as targeted MR contrast agents for imaging of PCa needs to be further
validated using in vivo models. TCL-SPION–Apt bioconjugates can be used as therapeutic
carriers for the delivery of Dox, leading to selective delivery to PSMA-expressing cells
without significant loss in cytotoxicity. The lack of sensitive and specific imaging agents,
and effective therapeutic approaches for disseminated PCa, makes multifunctional
nanoparticle technologies, such as TCL-SPION–Apt bioconjugates, a potential approach for
both the detection and the treatment of disseminated PCa.[34–37] More broadly, the unique
advantages of such multifunctional nanoparticles with diagnostic and therapeutic capabilities
include: 1) targeted delivery of therapeutics to disease cells only, 2) observation of
therapeutic delivery, and 3) detection of therapeutic response. Through the use of other
disease-specific aptamers or other targeting molecules, as well as other strategies to
conjugate therapeutic agents, similar multifunctional nanoparticles can be developed for
applications in medicine.
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Experimental Section
TCL-SPION–Apt bioconjugate
A solution of carboxy-TCL-SPION (50 μL, 1.5 mg)[29] was treated with N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) (25 μL, 400 mM) and N-
hydroxysuccinimide (NHS) (25 μL, 100 mM) and gently shaken for 15 min. N-terminated
Aptamer (RNA-TEC, Belgium, 1 mg in 100 μL) was then added, and the solution gently
shaken for a further 4 h. Unreacted aptamer was removed using centrifugal filtration, five
times (3,000 rpm, Nanosep centrifugal devices, 300 K, Pall Corp). Gel electrophoresis was
carried out on 1.8 % agarose gels; 0.05 mg of TCL-SPION–Apt bioconjugate and TCL-
SPION were loaded. Tris-acetate-EDTA (TAE) buffer was used for the electrophoresis
experiments. (Figure 1 b and Supporting Information, figure 1)
Iron (Prussian blue) stain
LNCaP and PC3 cell lines were grown in eight-well microscope chamber slides in
RPMI-1640 and Ham’s F-12 K medium respectively; both were treated with aqueous
penicillin G (100 U mL−1), streptomycin (100 μgmL−1), and 10 % fetal bovine serum
(FBS). Cells were grown to 70 % confluency (40 000 cells cm−2). Prior to dosing, cells were
washed with PBS buffer and incubated with fresh media for 30 min. Cells were dosed with
TCL-SPION–Apt bioconjugate or TCL-SPION (0.1 mgmL−1) (n=4) and incubated for 3–24
h at 37 °C, then washed two times with PBS and fixed with 4 % formaldehyde. The cells
were stained using the HT20 Iron Stain Kit (Sigma–Aldrich), and imaged with light
microscopy.
Quantification of Dox loading
The amount of Dox loading onto TCL-SPION–Apt bioconjugate was calculated by
fluorescence titration method. Before titration, the concentrations of TCL-SPION and TCL-
SPION–Apt bioconjugate were determined from a standard curve of TCL-SPION at 310 nm
(data not included).[22] Increasing concentrations of TCL-SPION (7.46 mgmL−1; 5, 15, 30,
36, 52, 100, 150, 260, 360 and 520 μg) or TCL-SPION–Apt bioconjugate (6.3 mgmL−1; 4,
13, 22, 31, 44, 88, 133, 220, 311 and 440 μg) were added stepwise to a fixed concentration
of Dox (12 μg in 0.45 mL). After each addition, the solution was mixed well and incubated
at room temperature for 10 min. The fluorescence spectra were recorded by exciting the
solution at 480 nm and recording the emission at 500–720 nm (3 mm slit) on a Shimadzu
RF-PC100 spectrofluorophotometer. The maximum loading amount was defined as the
concentration of nanoparticle required to give a 95 % reduction in fluorescence emission
compared with the spectra of an untreated solution of Dox.
T1 and T2 relaxation time measurements
LNCaP and PC3 cell lines were grown in six-well plates to ~100 % confluency. Prior to
dosing, cells were washed with PBS buffer and incubated with fresh media for 30 min. Cells
were dosed with TCL-SPION–Apt bioconjugate or TCL-SPION (0.1 mgmL−1)(n=4) and
incubated for 6 h at 37 °C, then washed two times with PBS, detached with trypsin, and
fixed with 4 % formaldehyde. Approximately one million cells of each sample were
resuspended in 100 μL of Matrigel and placed inside a standard eight-well strip (Greiner
Bio-One). Measurements were performed on a single-sided NMR probe at 25 °C at an
operating frequency of 18.55 MHz (Profile NMR MOUSE, ACT Center for Technology,
Aachen, Germany). A Minispec spectrometer (Bruker Optics, The Woodlands, TX, USA)
was used for pulse sequence generation and data acquisition. A computer-controlled motion
stage (Newport Corporation, Irvine, CA) positioned each well over the sensitive volume,
and custom software, written in LabView (National Instruments, Austin, TX), coordinated
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the measurements. The acquisition time was approximately 30 s per sample. The
longitudinal relaxation time T1 was measured using a saturation recovery sequence. The
signal intensity was measured with a short Carr Purcell Meiboom Gill (CPMG) echo
sequence following a saturation pulse sequence, and a recovery time Δ. The echo time, TE,
was 0.035 ms and 114 echoes were acquired for each time point. Seven time points were
acquired per sample. The transverse relaxation time, T2, was measured using a CPMG pulse
sequence lasting 200 ms with an echo time of 0.035 ms. The data were averaged over 16
scans and the recovery time (TR) was 1.25 s for Sample 2 and 2.5 s for the others. The NMR
sensor’s static field gradient contributes to lower T2 values and limits the maximum
measurable T2. The measured T2 values were all within the operating range of the
instrument. The data were fit using a custom script running on MATLAB (The Mathworks,
Natick, MA).
(1)
MTT cell proliferation assay
LNCaP and PC3 cell lines were grown in 48-well plates in RPMI-1640 and Ham’s F-12 K
medium, respectively; both were treated with aqueous penicillin G (100 U mL−1),
streptomycin (100 μgmL−1), and 10 % FBS, at concentrations so as to allow 70 %
confluence in 24 h (~40000 cells cm−2). Prior to dosing, cells were washed with PBS buffer
and incubated with fresh media for 30 min.
Cells were dosed with TCL-SPION–Apt(Dox) bioconjugates (0.1 mgmL−1, 5 μM Dox),
TCL-SPION (0.1 mgmL−1), or free Dox (5 μM) and incubated for 3 h at 37 °C, then washed
two times with PBS, and further incubated in fresh growth media for a total of 48 h. Cell
viability was assessed colorimetrically with the MTT reagent (ATCC) following the
standard protocol provided by the manufacturer. The absorbance was read with a microplate
reader at 570 nm.
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Figure 1.
a) Schematic illustration of the TCL-SPION–Apt bioconjugate system; b) confirmation of
TCL-SPION–Apt bioconjugate formation by gel electrophoresis (1. 100-bp ladder; 2. A10
aptamer; 3. TCL-SPION–Apt bioconjugate; 4. TCL-SPION).
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Figure 2.
Prussian blue stained LNCaP and PC3 cells after incubation with TCL-SPION–Apt
bioconjugate and non-targeted TCL-SPION.
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Figure 3.
a) T1 longitudinal relaxation times of LNCaP (■) and PC3 ( ) cells incubated with TCL-
SPION and TCL-SPION–Apt bioconjugates; b) T2 transverse relaxation times of LNCaP (■)
and PC3 ( ) cells incubated with TCL-SPION and TCL-SPION–Apt bioconjugates.
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Figure 4.
Fluorescence spectra of doxorubicin solution (12 μg in 0.45 mL) with increasing amounts of
a) TCL-SPION (from top to bottom: 5, 15, 30, 36, 52, 100, 150, 260, 360, and 520 μg) and
b) TCL-SPION–Apt (from top to bottom: 4, 13, 22, 31, 44, 88, 133, 220, 311, and 440 μg).
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Figure 5.
MTT cell proliferation assay (LNCaP ■; PC3 ; * p<0.005, n=3).
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